Published in J Biol Chem on March 15, 2010
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med (2012) 4.90
Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer (2011) 3.55
CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies. Cancer Res (2012) 0.97
Regulation of Bim in Health and Disease. Oncotarget (2015) 0.95
BEX1 promotes imatinib-induced apoptosis by binding to and antagonizing BCL-2. PLoS One (2014) 0.85
Gefitinib-resistance is related to BIM expression in non-small cell lung cancer cell lines. Cancer Biother Radiopharm (2012) 0.83
The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRα. PLoS One (2013) 0.80
Oncogenic Kit signals on endolysosomes and endoplasmic reticulum are essential for neoplastic mast cell proliferation. Nat Commun (2014) 0.80
Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumors. Oncogene (2017) 0.79
Correlation of glucocorticoid-mediated E4BP4 upregulation with altered expression of pro- and anti-apoptotic genes in CEM human lymphoblastic leukemia cells. Biochem Biophys Res Commun (2014) 0.78
Evaluating new therapies in gastrointestinal stromal tumor using in vivo molecular optical imaging. Cancer Biol Ther (2014) 0.77
Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells. Oncotarget (2014) 0.76
M-COPA suppresses endolysosomal Kit-Akt oncogenic signalling through inhibiting the secretory pathway in neoplastic mast cells. PLoS One (2017) 0.75
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet (2004) 11.37
Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol (2000) 6.05
Biology of gastrointestinal stromal tumors. J Clin Oncol (2004) 5.89
BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med (2007) 4.50
Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene (2003) 3.96
Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med (2007) 3.58
Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci (2009) 3.54
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene (2001) 3.36
Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med (2007) 3.09
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci U S A (2006) 3.06
FOXOs, cancer and regulation of apoptosis. Oncogene (2008) 3.02
Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol (2008) 2.85
Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene (2005) 2.80
Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function. J Biol Chem (2005) 2.27
Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest (2008) 2.17
Multisite phosphorylation regulates Bim stability and apoptotic activity. Mol Cell (2008) 2.16
Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res (2007) 2.10
Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res (2006) 2.04
KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene (2007) 1.84
Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene (2004) 1.82
Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Pigment Cell Melanoma Res (2007) 1.80
Bim and the pro-survival Bcl-2 proteins: opposites attract, ERK repels. Cell Cycle (2007) 1.68
Oncogenic B-RafV600E inhibits apoptosis and promotes ERK-dependent inactivation of Bad and Bim. J Biol Chem (2008) 1.32
Inhibition of glucocorticoid-induced apoptosis by targeting the major splice variants of BIM mRNA with small interfering RNA and short hairpin RNA. J Biol Chem (2004) 1.29
Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate. Cancer Res (2007) 1.27
Cytokines direct the regulation of Bim mRNA stability by heat-shock cognate protein 70. Mol Cell (2007) 1.22
Making progress through molecular attacks on cancer. Cold Spring Harb Symp Quant Biol (2005) 1.18
The stem cell factor receptor/c-Kit as a drug target in cancer. Curr Cancer Drug Targets (2006) 1.15
Imatinib mesylate induces quiescence in gastrointestinal stromal tumor cells through the CDH1-SKP2-p27Kip1 signaling axis. Cancer Res (2008) 1.07
Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells. Cancer Res (2006) 1.07
Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs. Blood (2009) 1.04
Gastrointestinal stromal tumor: a clinical overview. Hematol Oncol Clin North Am (2009) 1.01
Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells. Cancer Res (2009) 0.95
Biology of gastrointestinal stromal tumors: KIT mutations and beyond. Cancer Invest (2004) 0.93
Is autophagy rather than apoptosis the regression driver in imatinib-treated gastrointestinal stromal tumors? Transl Oncol (2008) 0.82
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46
Chromatin structure analyses identify miRNA promoters. Genes Dev (2008) 5.40
High-throughput mapping of the chromatin structure of human promoters. Nat Biotechnol (2007) 5.24
Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell (2007) 4.75
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res (2010) 4.71
MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med (2006) 4.60
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28
Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev (2006) 4.24
Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell (2002) 3.72
BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol (2005) 3.68
Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell (2013) 3.63
Melanocyte biology and skin pigmentation. Nature (2007) 3.43
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20
Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol (2008) 3.16
Mechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche. Science (2004) 3.12
A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature (2011) 2.96
Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell (2004) 2.80
GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature (2009) 2.77
Melanoma: from mutations to medicine. Genes Dev (2012) 2.59
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature (2012) 2.35
Microphthalamia-associated transcription factor: a critical regulator of pigment cell development and survival. Oncogene (2003) 2.19
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11
Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning. Nature (2006) 2.09
Key roles for transforming growth factor beta in melanocyte stem cell maintenance. Cell Stem Cell (2010) 2.06
Beta-catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor. J Cell Biol (2002) 2.00
An oncogenic role for ETV1 in melanoma. Cancer Res (2010) 1.94
TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res (2007) 1.93
MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma. Am J Pathol (2003) 1.90
Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. Mol Cell (2010) 1.86
NFATc2-mediated repression of cyclin-dependent kinase 4 expression. Mol Cell (2002) 1.79
UV and pigmentation: molecular mechanisms and social controversies. Pigment Cell Melanoma Res (2008) 1.78
A polymorphism in IRF4 affects human pigmentation through a tyrosinase-dependent MITF/TFAP2A pathway. Cell (2013) 1.75
Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res (2008) 1.73
Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation. Proc Natl Acad Sci U S A (2003) 1.73
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A (2013) 1.72
Pycnodysostosis: role and regulation of cathepsin K in osteoclast function and human disease. Curr Mol Med (2002) 1.69
Transcriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanoma. Cancer Res (2004) 1.64
Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis. J Biol Chem (2005) 1.62
Regulation of MITF stability by the USP13 deubiquitinase. Nat Commun (2011) 1.62
Control of melanocyte differentiation by a MITF-PDE4D3 homeostatic circuit. Genes Dev (2010) 1.61
Transdifferentiation of the retina into pigmented cells in ocular retardation mice defines a new function of the homeodomain gene Chx10. Development (2004) 1.58
Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol (2005) 1.54
Biology and clinical relevance of the micropthalmia family of transcription factors in human cancer. J Clin Oncol (2011) 1.47
c-Met expression is regulated by Mitf in the melanocyte lineage. J Biol Chem (2006) 1.42
Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers. Cancer Cell (2006) 1.41
Sumoylation of MITF and its related family members TFE3 and TFEB. J Biol Chem (2004) 1.40
Genomic analysis of the Microphthalmia locus and identification of the MITF-J/Mitf-J isoform. Gene (2005) 1.35
How sunlight causes melanoma. Curr Oncol Rep (2010) 1.34
A new era: melanoma genetics and therapeutics. J Pathol (2010) 1.32
Lineage-specific transcriptional regulation of DICER by MITF in melanocytes. Cell (2010) 1.31
Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations. Am J Clin Pathol (2002) 1.30
SKI activates Wnt/beta-catenin signaling in human melanoma. Cancer Res (2003) 1.22
Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis. Dev Cell (2010) 1.22
Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage. Pigment Cell Melanoma Res (2008) 1.21
Feed-forward microprocessing and splicing activities at a microRNA-containing intron. PLoS Genet (2011) 1.18
Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17
Quantitative assessment of Tet-induced oxidation products of 5-methylcytosine in cellular and tissue DNA. Nucleic Acids Res (2013) 1.16
Identification of Aim-1 as the underwhite mouse mutant and its transcriptional regulation by MITF. J Biol Chem (2001) 1.16
A melanoma molecular disease model. PLoS One (2011) 1.15
Microphthalmia transcription factor and PU.1 synergistically induce the leukocyte receptor osteoclast-associated receptor gene expression. J Biol Chem (2003) 1.14
Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. Cancer Res (2010) 1.14
BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. Oncoimmunology (2013) 1.13
NF-kappa B2 p100 is a pro-apoptotic protein with anti-oncogenic function. Nat Cell Biol (2002) 1.12
Mitf and Tfe3: members of a b-HLH-ZIP transcription factor family essential for osteoclast development and function. Bone (2004) 1.10
Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF. Proc Natl Acad Sci U S A (2011) 1.09
The identification and functional characterization of a novel mast cell isoform of the microphthalmia-associated transcription factor. J Biol Chem (2002) 1.08
PGC-1 coactivators regulate MITF and the tanning response. Mol Cell (2012) 1.07
A tissue-restricted cAMP transcriptional response: SOX10 modulates alpha-melanocyte-stimulating hormone-triggered expression of microphthalmia-associated transcription factor in melanocytes. J Biol Chem (2003) 1.07
Inhibition of the met receptor in mesothelioma. Clin Cancer Res (2005) 1.05
Epistatic connections between microphthalmia-associated transcription factor and endothelin signaling in Waardenburg syndrome and other pigmentary disorders. FASEB J (2007) 1.02
New strategies in metastatic melanoma: oncogene-defined taxonomy leads to therapeutic advances. Clin Cancer Res (2011) 1.02
Indoor ultraviolet tanning and skin cancer: health risks and opportunities. Curr Opin Oncol (2009) 1.02
Validation of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinomas. Diagn Mol Pathol (2011) 1.01
Expression of the neural stem cell markers NG2 and L1 in human angiomyolipoma: are angiomyolipomas neoplasms of stem cells? Mol Med (2007) 1.01
Role for microphthalmia transcription factor in the diagnosis of metastatic malignant melanoma. Appl Immunohistochem Mol Morphol (2002) 1.00
Hyaluronan inhibits osteoclast differentiation via Toll-like receptor 4. J Cell Sci (2006) 1.00
Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation. Clin Cancer Res (2014) 0.98
Transcriptional regulation in melanoma. Hematol Oncol Clin North Am (2009) 0.98
YY1 regulates melanocyte development and function by cooperating with MITF. PLoS Genet (2012) 0.93
Lighting a path to pigmentation: mechanisms of MITF induction by UV. Pigment Cell Melanoma Res (2010) 0.91
The microphthalmia transcription factor (Mitf) controls expression of the ocular albinism type 1 gene: link between melanin synthesis and melanosome biogenesis. Mol Cell Biol (2004) 0.91
MiT transcription factor associated malignancies in man. Cell Cycle (2007) 0.90
Dual roles of lineage restricted transcription factors: the case of MITF in melanocytes. Transcription (2012) 0.90
Mechanism of regulation and suppression of melanoma invasiveness by novel retinoic acid receptor-gamma target gene carbohydrate sulfotransferase 10. Cancer Res (2009) 0.88
How does pheomelanin synthesis contribute to melanomagenesis?: Two distinct mechanisms could explain the carcinogenicity of pheomelanin synthesis. Bioessays (2013) 0.88
Key discoveries in melanocyte development. J Invest Dermatol (2011) 0.87
Specification and loss of melanocyte stem cells. Semin Cell Dev Biol (2008) 0.87
Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma. Nat Clin Pract Oncol (2008) 0.85
Induction of apoptosis in cancer: new therapeutic opportunities. Ann Med (2002) 0.85
Notch and melanocytes: diverse outcomes from a single signal. J Invest Dermatol (2008) 0.84
Transcription factor E3, a major regulator of mast cell-mediated allergic response. J Allergy Clin Immunol (2012) 0.84
Dynamic and transient cancer stem cells nurture melanoma. Nat Med (2010) 0.84
Central role for cAMP signaling in pigmentation and UV resistance. Cell Cycle (2011) 0.83
Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma. J Natl Cancer Inst (2012) 0.82
Developing melanoma therapeutics: overview and update. Wiley Interdiscip Rev Syst Biol Med (2013) 0.82
Stemming the tanning bed epidemic: time for action. J Natl Compr Canc Netw (2012) 0.82
Melanoma and viagra: an unexpected connection. Pigment Cell Melanoma Res (2011) 0.81
Teens and indoor tanning: a cancer prevention opportunity for pediatricians. Pediatrics (2013) 0.81